Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This is a treatment protocol designed only to provide access to everolimus (RAD) for maintenance immunosuppression. The objectives are to facilitate the management of patients on maintenance immunosuppression therapy who are completing everolimus trials,
* To provide everolimus maintenance therapy through this access program and
* To collect and review safety data for up to 120 months or until the project has been discontinued whichever comes first.
* To collect and review safety data for up to 120 months or when Certican is commercially available in the given indication and reimbursed by appropriate payors or the project has been discontinued whichever comes first.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female recipients of solid organ transplants
Subject is currently enrolled in an everolimus (RAD) trial sponsored by Novartis
Currently on investigational drug everolimus (RAD) therapy
You may not be if
Inability or unwillingness to comply with immunosuppressive regimen.
Pregnancy.
History of acute organ rejection within the last 3 months.
Clareo Health | A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
